NCT01761240View on ClinicalTrials.gov

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 19, 2013

Primary Completion Date

February 9, 2016

Study Completion Date

February 9, 2016

Conditions
Breast CancerPancreatic CancerColorectal CancerCarcinoma, Non-Small-Cell LungAdenocarcinoma
Interventions
DRUG

MORAb-066

MORAb-066 infusion.

Trial Locations (2)

Unknown

Oklahoma City

Nashville

Sponsors

Lead Sponsor

Morphotek
All Listed Sponsors
collaborator

SCRI Development Innovations, LLC

OTHER

lead

Morphotek

INDUSTRY